feedback

Course Director

Robert Z. Orlowski, MD, PhD
Robert Z. Orlowski, MD, PhD

The University of Texas MD Anderson Cancer Center
Houston, Texas

Accredited by

Penn State College of Medicine

Activity Details

Credit Types:CME / CNE
Credit Amount:1.0 Credits
Release Date:2019-Aug-08
Expiration Date:2020-Aug-07
Estimated Time for Completion:60 minutes
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

In this activity, an expert in the management of MM discusses the implications of recent efficacy and safety data that support the ongoing integration and use of several innovative treatments, such as antibody-based therapies, next-generation IMiDs and proteasome inhibitors, and novel therapies directed against intracellular targets. The expert also provides a review of the overall shape of MM therapy in newly diagnosed and relapsed disease, and discusses strategies to manage treatment-related adverse effects.

Upon completion of this activity, participants will be able to:
  • Summarize updated evidence on the use of novel agent classes and next-generation therapeutics in multiple myeloma (MM), including proteasome inhibitors, immunomodulators (IMiDs), novel antibodies, and targeted agents
  • Select appropriate therapy in patients with newly diagnosed MM, including those requiring eradication of MRD or treatment for high-risk disease
  • Recommend therapy with novel components for patients with early relapse or treatment-refractory MM
  • Manage treatment-related adverse events in patients with MM who are receiving novel therapeutics as part of their care

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, oncologists, oncology nurses, and other healthcare providers involved in the care of patients with MM.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 80% or higher is needed to obtain CME credit and 70% or higher to obtain CNE credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/CNE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: August 08, 2019 - August 07, 2020
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Penn State College of Medicine and Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Course Director

Robert Z. Orlowski, MD, PhD
Florence Maude Thomas Cancer Research Professor
Director, Myeloma Section, Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas

Robert Z. Orlowski, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; Celgene Corporation; GlaxoSmithKline; Ionis Pharmaceuticals, Inc.; Juno Therapeutics; Kite Pharma, Inc.; Legend Biotech; Molecular Partners; Servier Pharmaceuticals LLC.; and Takeda Pharmaceutical Company Limited.
Pre-clinical laboratory-based research support for BioTheryX, Inc.

Robert Z. Orlowski, MD, PhD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: daratumumab-containing quadruplet therapy, lenalidomde-dexamethasone in smoldering myeloma, venetoclax, isatuximab, and anti-BCMA antibodies and CAR T cell therapy.

Content Reviewers

Tracy L. Greene, MSN, RN, FNP-C, Lead Nurse Planner, has no financial interests/relationships or affiliations in relation to this activity.

Gina Cravey, BSN, RN, CHRC, CCRC, has no financial interests/relationships or affiliations in relation to this activity.

Medical Directors

Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

Laura Healy
PVI, PeerView Institute for Medical Education

Laura Healy has no financial interests/relationships or affiliations in relation to this activity.

Other PVI associates who are in a position to have control over the content of this activity, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CNE activity during the past 12 months.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

The associates of the Medical Learning Institute, Inc., the accredited CNE provider for this activity, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CNE activity during the past 12 months.

Disclaimer

The information provided at this CME/CNE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit, and Support

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Penn State College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # A6504-20-T.

Nurses

Medical Learning Institute, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Successful completion of this continuing nursing education activity will be awarded 1.0 contact hour(s).

Providership


This CME/CNE activity is jointly provided by Penn State College of Medicine and PVI, PeerView Institute for Medical Education; this activity is also co-provided by Medical Learning Institute, Inc.

Support

This activity is supported through educational grants from Bristol-Myers Squibb, Celgene Corporation, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Karyopharm Therapeutics, Inc., and Sanofi Genzyme.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME/CNE Activity

PVI, PeerView Institute for Medical Education, Penn State College of Medicine, and Medical Learning Institute, Inc. are responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI, Penn State College of Medicine, and Medical Learning Institute, Inc. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. For approved prescribing information, please consult the manufacturer's product labeling. No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our activities. No responsibility is taken for errors or omissions in activities.

Copyright © 2000-2019, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.